Program and charges of $
571
million for our Realigning our Cost Base Program), $
1.5
billion for 2023 (including charges of $
1.4
billion for our Realigning our Cost Base Program and charges of $
3
million for our Transforming to a More Focused Company program, that we have substantially completed) and $
796
million for 2022 (including charges of $
601
million for our Transforming to a More Focused Company program).
(b)
Represents external costs for banking, legal, accounting and other similar services.
(c)
Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. 2023 costs mostly relate to our acquisition of Seagen, including $
476
million that was recognized as a post-closing compensation expense for payments to Seagen employees in the fourth quarter of 2023 for the fair value of long-term incentive awards that vested upon closing and the expense for employee incentive awards issued in contemplation of the merger. 2022 costs mostly related to our acquisitions of Arena and GBT, including $
138
million in payments to Arena employees in the first quarter of 2022 and $
136
million in payments to GBT employees in the fourth quarter of 2022 for the fair value of previously unvested long-term incentive awards that was recognized as post-closing compensation expense. See
Note 2A
.
Notes to Consolidated Financial Statements
Pfizer Inc. and Subsidiary Companies
(d)
Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)
Represents external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
(a)
Other activity includes adjustments for foreign currency translation that are not material to our consolidated financial statements.
(b)
Included in
Other current liabilities
($
1.3
billion) and
Other noncurrent liabilities
($
663
million).
(c)
Included in
Other current liabilities
($
1.7
billion) and
Other noncurrent liabilities
($
437
million).
Note 4.
Other (Income)/Deductionsâ€”Net
(a)
Capitalized interest totaled $
182
million in 2024, $
160
million in 2023 and $
124
million in 2022.
(b)
The increase in net interest expense in 2024 reflects (i) a decrease in interest income due to lower investment balances after completion of our $
43.4
billion Seagen acquisition in December 2023 and (ii) higher interest expense driven by our $
31
billion aggregate principal amount of senior unsecured notes issued in May 2023, as well as the remaining balance of the $
8
billion of commercial paper issued in the fourth quarter of 2023, both part of the financing for our acquisition of Seagen.
(c)
2024 net gains primarily include, among other things, an unrealized gain of $
1.0
billion related to our investment in Haleon, which is now carried at fair value (see
Note 2C
). 2023 net gains primarily included,